CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 68 enrolled
Drug / intervention
Ethyl-Eicosapentaenoic Acid (E-EPA)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04152291
NCT04152291N/ACompleted
CompareCT.gov

The Effect of Ethyl Eicosapentaenoic Acid on Circulating Low-density Lipoproteins and Plasma Lipid Metabolism in Healthy Volunteers

Wihuri Research Institute·interventional·Posted Nov 5, 2019·Updated Sep 22, 2025

In Brief

A clinical study evaluating Ethyl-Eicosapentaenoic Acid (E-EPA) for Atherosclerosis and 3 related conditions. Completed, enrolled 68 participants across 1 site.

Detailed Summary

40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month. Blood samples will be collected before the study and at weeks 1 and 4 and also, two weeks after finishing the diet. Main study focuses are LDL aggregation susceptibility, lipid composition and proteoglycan binding affinity. In addition, important plasma lipid metabolism enzymes and lipid mediated resolvins are measured as well as several baseline characteristics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition, Cardiovascular Diseases
CountriesFinland
CollaboratorsUniversity of Helsinki

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 5, 2019
Enrollment StartNov 12, 2019
Primary CompletionJun 30, 2024
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.7 years ago

Interventions

Ethyl-Eicosapentaenoic Acid (E-EPA)dietary

3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.